Here is a little market riddle. In the US you effectively have ACG's device and soon, UCM's device which can be reimbursed. ACG sell their's for USD20k+, whilst UCM sell theirs for USD3.5k. Studies have shown UCM>ACG and a few have shown ACG's can struggle for accuracy if patients have certain conditions (i.e. diabetes). Not counting the fact that ACG grossly overpromised expected reimbursement rates (USD40+ initially), rates average USD17 per test. Who do you think is going to sell devices better?
Ann: Preliminary and Annual Report to shareholders-UCM.AX, page-2
Add UCM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.26M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 23000 | 1 |
View Market Depth
| Last trade - 16.12pm 08/11/2024 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable